Objective: To examine associations between diabetes mellitus and clinical markers of benign prostatic hyperplasia in community-dwelling white and black men aged 40-79 years.
enign prostatic hyperplasia (BPH) and Type 2 diabetes mellitus (DM) are both highly prevalent conditions which bring millions of older American men to medical attention each year. Typically, clinicians treat BPH and DM as separate entities although some have suggested that diabetes may be a risk factor for the development and progression of BPH.
(1-3) Clinical uncertainty stems from the fact that both diabetic neuropathy and BPH can lead to dysfunctional bladder storage and emptying which makes it difficult to determine the extent to which diabetes and/or BPH contributes to voiding dysfunction in these patients. In order to more clearly understand the association between diabetes and BPH it is important to examine the full spectrum of clinical markers of BPH including lower urinary tract symptoms (LUTS), urinary flow, prostatic volume and serum prostatespecific antigen (PSA) concentrations.
Recently, the National Health and Nutrition Examination Survey reported the prevalence of diabetes to be greater in blacks than in whites. Specifically, the prevalence in black men aged 40-59 is 9.6% increasing to 29.2% in men 65 years and older compared to 5.5% and 14.3%, respectively, in whites.(4) Moreover, in a previous study, we observed a significantly greater report of moderate/severe LUTS in black men as compared to white men suggesting a potential racial difference in BPH.(5) If diabetes and BPH are indeed related, these racial disparities, along with the dramatic increase in the incidence of Type 2 diabetes in the past decade, have striking implications for the black male population and underscore the need to understand this more completely.
The Olmsted County Study of Urinary Symptoms and Health Status (OCS) has served as a point of reference for prevalence and incidence estimates of measures of BPH in community-dwelling men. (6) However, the lack of black men in the OCS has limited its ability to evaluate racial differences. To fill this void, the Flint Men's Health Study (FMHS) was developed as a comparable community-based study of black men designed to mirror the OCS protocol. (7) In this study we examine the associations between diabetes and clinical markers of BPH and determine whether race modifies these relationships. We did this by combining these two large comparable ongoing epidemiological studies of community-dwelling men aged 40-79.
MATERIALS AND METHODS
Subjects. Details on subject selection for both the OCS and FMHS have been previously published. (8, 9) Briefly (15, 16) in the current report.
Finally, information regarding marital status, education, income levels and body mass index (based on selfreported weight/height 2 ) were gathered by questionnaire in both the OCS (n=2,115) and FMHS (n=369). Statistical analysis. Distributions of the clinical markers of BPH were evaluated overall and by diabetes status after data elements from the OCS and FMHS were combined. Differences in median AUASI scores, individual symptoms, prostate volume, peak urinary flow rate and total PSA levels by diabetes status were tested univariately on a continuous scale (Kruskal-Wallis test) and using standard dichotomous cut-points(10)(chi-square test).
Multivariable associations were also explored using logistic regression models, adjusting for race, age, body mass index (BMI) and various indicators of socioeconomic status (SES) including: marital status, education and income. An interaction term defined by the crossproduct of race and diabetes status was included in all models to examine the potential for racial differences in the associations between diabetes and markers of BPH. Racial differences in these associations were also examined using the Breslow-Day test for homogeneity of odds ratios which yielded the same results as the multivariable approach described above. All analyses were performed using SAS (SAS Institute, Cary, NC).
RESULTS
Among the 2,484 total participants (2,115 white and 369 black men), 170 (6.8%) had a self-reported history of diabetes. (Table 1 ) The mean ± SD age was 56.0 ± 10.5 years overall and 62.4 ± 10.4 and 55.5 ± 10.4 in those with and without diabetes, respectively (p<0.0001). Overall, 68.3% of men were overweight/obese (BMI≥25) with 82.9% and 67.2% being overweight/obese among diabetic and non-diabetic men, respectively (p<0.0001). Black men had an increased odds of having diabetes, age-adjusted OR=3.96 (95%CI=2.82, 5.56).
In bivariate analyses, men with diabetes had significantly greater median AUASI scores (7 vs. 5, p<0.0001). (Table  2 ) Median prostate volume was also higher among these men (30.24 cc vs. 26.01 cc, p=0.008), while peak urinary flow rates were significantly lower (15.2 ml/sec vs. 17.4 ml/sec, p=0.02). No significant differences were found in median PSA levels; however, the frequency of men with PSA levels at or above 2.5 ng/mL was significantly greater among those with diabetes (p=0.04). The frequency of irritative symptoms was also notably higher among diabetic men (57% vs. 39%). No significant differences were observed for obstructive symptoms.
In (3) This study, however, relied on a control group from a referral population that did not meet the specified exclusion criteria for BPH, and thus likely underestimated the effect of diabetes on LUTS. Furthermore, in contrast to their finding for BPH surgery, the Normative Aging Study found a nonsignificant inverse association between diabetes and clinical BPH (23). Finally, in the OCS, Burke et al. observed that diabetic men reported a larger increase in the AUASI score than did non-diabetic men. However, they found no differences in change of prostate volume suggesting, perhaps, that the presence of diabetes may be less directly associated with prostate growth and more closely associated with the dynamic components of lower urinary tract function. (24) . Importantly some of the aforementioned studies utilized markers of BPH (e.g., trans-urethral resection of the prostate) to define disease. These markers can be a poor endpoint for LUTS in diabetic men whose LUTS could be a result of bladder dysfunction.(25) Furthermore, the failure to differentiate LUTS from BPH, along with the lack of inclusion of additional clinical markers more specific to BPH may have contributed to the confusing evidence now seen in the literature.(25) Finally, these studies were limited by their inclusion of primarily white men and lack of population-based samples,(26,27) which the designs of the FMHS and OCS overcome.
In this study, we observed that diabetes was significantly associated with increased irritative symptom severity. While we also observed that diabetes was associated with increased overall LUTS severity, increased prostate volume, increased serum PSA levels and decreased urinary flow rates, these findings were not statistically significant and suggest that there is no strong evidence for an association between DM and BPH across measures. Given the lack of evidence with measures more specific to prostate disease, the association observed between diabetes and irritative LUTS is likely attributed to diabetic neuropathy and is largely driven in this study by the significant association observed specifically between DM and nocturia. One explanation for this finding is that poorly managed diabetes in black men compared to white men would lead to increased thirst and subsequent nocturia. Although nocturia may be a consequence of changes in bladder reservoir function and/or kidney function secondary to urinary tract obstruction, nocturia has been associated with diabetes in numerous reports. (28) (29) (30) There are several mechanisms by which diabetes may influence BPH. The first is via changes in insulin concentrations which may, in turn, influence sex hormone concentrations,(31) sympathetic nerve activity and/or the insulin-like growth factor axis and affect the growth of the prostate (18, 32) . In addition, poorly controlled diabetes can cause osmotic diuresis which may be associated with urinary frequency and nocturia and also affect LUTS via neuropathic mechanisms, influencing both motor and sensory nerves.(33) These findings are important for several reasons. Although we did not observe statistically significant associations between DM and more specific measures of BPH, the magnitude and direction of the associations observed across the spectrum of BPH measures suggest that potentially, diabetes may influence not only the dynamic components of lower urinary tract function via the bladder but may even influence prostatic growth. This is evidenced specifically in the marginal positive association observed between diabetes and prostate volume among black men. This observation could be explained, in part, by IGF-1 and IGFBP-3 concentrations found to not only vary by race but also associated with prostate growth. (34, 35) As both BPH and diabetes are highly prevalent conditions of significant burden in the US, the potential of prostate disease as complication of diabetes warrants further investigation in study populations with larger samples of men with diabetes.
We also observed that the association between diabetes and irritative LUTS severity was increased among black men. The findings of racial differences in the relationship between DM and LUTS is consistent with previous findings from this cohort, supporting racial disparities in LUTS. (5) However, it remains unclear whether this disparity is secondary to an underlying biologic difference in the manifestation of metabolic disease, differences in perception of symptoms or both. The increased burden of diabetes in black men in this country along with our observed finding of a stronger association between diabetes and LUTS in black men suggests the potential impact of diabetes on bladder etiology could be of significant concern in this subset of the US population.
Although this is the first study to examine the association between diabetes and clinical markers of BPH in a multiethnic population-based sample of men, there are several limitations that should be considered. First, the crosssectional nature of the study limits our interpretation of causal relationships between diabetes and BPH within or between races. Second, this study relies on self-reported history of physiciandiagnosed diabetes which may result in the inclusion of individuals with diabetes in the control group or vice versa. It is possible that this misclassification is related to healthcare utilization which may be influenced by both race and SES. However, this misclassification is not likely to be differential by markers of BPH and would most likely result in an underestimation of the association between BPH markers and diabetes. In addition, the most severe cases of diabetes were excluded from the OCS cohort due to the exclusion of individuals with end-organ damage.(36) This coupled with the higher prevalence of diabetes in the FMHS could have contributed to the greater magnitude of the estimate of association in black men observed in this study.
Finally, although the findings reveal positive associations between diabetes and various clinical markers of BPH, we cannot exclude the possibility of chance as an explanation for our findings as the confidence intervals for the multivariable estimates include one. This could likely be attributed to the limited sample size available among the clinical subset. Moreover, the resulting changes with the inclusion of the SES indicators specifically with LUTS severity are consistent with the notion that perhaps indicators of socioeconomic status (i.e. education) affects perception rather than actual occurrence of symptoms. (5) However, this is the first study with comprehensive clinical data regarding measures of BPH and estimating the magnitude of the association between BPH and DM is an important first step in determining whether relationships indeed exist.
These potential limitations are offset by the strengths of this study, including a population-based multiethnic sample of men with comprehensive set of clinical markers of BPH.
CONCLUSIONS
In this community-based study of BPH and diabetes, we have demonstrated associations between diabetes and increased irritative LUTS severity, specifically nocturia. Moreover, the magnitude of the association between irritative LUTS and diabetes is increased in black men. Furthermore, there was no strong evidence for an association between DM and BPH across measures more specific to BPH (i.e. prostate volume, PSA and peak urinary flow rate). Taken together, our findings suggest that the presence of diabetes may be less related to prostate growth and more related to the dynamic components of lower urinary tract function. Further evaluations of the association between diabetes and BPH and any racial variation in this association are warranted. 
